GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2012

LIMR Licenses Antibody Tools to Rockland Immunochemicals

  • Rockland Immunochemicals inked a licensing venture with LIMR Development (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR). Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.

    LDI’s antibodies bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression. “LIMR's work in cancer and inflammation is an elegant fit with Rockland's antibody portfolio and technology platform,” remarks James Fendrick, president and CEO of Rockland Immunochemicals.

    “We partner with leading institutions to bring to researchers the reagents vital to the advance of their key research,” Fendrick adds. Rockland Immunochemicals focuses on antibodies and antibody-based tools for basic research, diagnostic assay development, and preclinical studies. It develops new technologies for the production of antibodies for western blotting, immunohistochemistry, immunofluorescence microscopy, ELISA, and flow cytometry.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?